Recent Updates
Recently added Catalysts

SNDL Inc.

SNDLFDA catalysts, PDUFA dates & pipeline intelligence
$1.24
▼ -0.1 · -7.46%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SNDL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.1352W HIGH $2.34
Volume
1.29 M
Value Traded
1.66 M
Short % Float
0.85%
Days to Cover
1.7
-10.79%Week
-3.13%1 Month
-6.77%3 Month
-15.65%6 Month

Cash Data

Unlock SNDL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
319.07 M
EPS (TTM)
-0.04
P/E Ratio
-
Ent. Value
292.95 M
Total Shares
257.32 M
Float Shares
236.31 M
Insiders
2.88%
Institutions
30.25%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every SNDL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SNDL Catalyst Timeline

Dated clinical, regulatory and corporate events for SNDL Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for SNDL Inc.

255Total events
3Upcoming
61Tier-1 (high impact)
2019 to 2028Coverage

Upcoming catalysts 2

T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details

Event history 50

●Quarterly UpdateCorporate
SNDL reports third quarter 2026 financial and operational results
▲Legal / SettlementCorporate
Restructuring of Parallel completed, reducing debt burden by ~US$842 million
▼Restructuring LayoffsCorporate
Reduction of more than 30% of workforce at Kelowna manufacturing facility
▲Dea SchedulingSafety
DOJ and DEA order placing FDA-approved cannabis products and qualifying state-regulated medical cannabis in Schedule III
●Legal / SettlementCorporate
Michigan Supreme Court agreed to hear oral argument on applications for leave to appeal in Skymint restructuring
◆Restructuring LayoffsCorporate
One-time restructuring investment of $11 million over 18 months
◆Quarterly UpdateCorporate
Q2 2025 financial results release
●Oral PresentationPresentation
Conference call and webcast for Q2 2025 results
◆AcquisitionCorporate
Special Meeting of 1CM shareholders to vote on transaction
●Quarterly UpdateCorporate
Q1 2025 financial and operational results reported
Unlock the full SNDL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SNDL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all SNDL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

SNDL Inc. is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every SNDL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every SNDL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SNDL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full SNDL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in SNDL for Q3 2026.
Unlock every fund holding SNDL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SNDL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SNDL ownership
Insider and institutional ownership, quarter by quarter.

SNDL Short Interest

Shares sold short, counted twice a month.

0.85%
Short % of Float
of tradable shares sold short
2.0M
Shares Sold Short
+0.5% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Unlock SNDL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock SNDL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SNDL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SNDL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SNDL ranks across every disease it competes in

Competitive Position is a premium feature
See how SNDL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SNDL News

-SNDL
Oct 27, 2026
SNDLGeneral

SNDL Reports Third Quarter 2026 Financial and Operational Results

SNDL Inc. reported its Q3 2026 results, showing a 2.5% decline in net revenue at $238.0 million. Despite a significant operating loss of $48.3 million, adjusted operating income returned to positive at $5.2 million. The company noted record free cash flow of $20.0 million and improvements in Cannabis Retail, though Cannabis Operations continued to struggle.

Read more →
-SNDL
Oct 15, 2026
SNDLGeneral

SNDL Announces 2026 Annual and Special Shareholders Meeting Results, Select Preliminary Third Quarter Results and Capital Return Initiatives

SNDL Inc. announced the results of its 2026 Annual and Special Meeting, where all five director nominees were elected. The company reported preliminary third quarter results, including a record free cash flow of approximately C$20 million. Shareholders also approved a share repurchase program, enhancing capital return initiatives.

Read more →
-SNDL
Oct 14, 2026
SNDLConferences/Events
▲ +5.2%on this newsshared move

SNDL to Report Third Quarter 2026 Financial Results on October 27, 2026

SNDL Inc. announced it will release its third quarter 2026 financial results on October 27, 2026. The results will be available before market opening, followed by a conference call at 10:00 a.m. EDT. SNDL is a major player in the cannabis and liquor retail sectors in Canada.

Read more →
-SNDL
Oct 6, 2026
SNDLGeneral

SNDL Announces Resignation of Director

SNDL Inc. announced the immediate resignation of Carlo Cannell from its Board of Directors. The company expressed gratitude for his contributions. SNDL is recognized as a major player in the cannabis and liquor retail sectors in Canada, operating several retail brands and investing strategically in the industry.

Read more →
-SNDL
Aug 4, 2026
SNDLGeneral

SNDL Announces Successful Completion of EU-GMP Audit at Atholville Facility

SNDL Inc. announced the successful completion of a European Union Good Manufacturing Practice audit at its Atholville facility. This achievement enhances SNDL's ability to engage in international medical cannabis markets. The company expects to receive EU-GMP certification within 90 days, reinforcing its commitment to quality and operational excellence.

Read more →
-SNDL
Jul 28, 2026
SNDLGeneral
▼ -9.6%on this news

SNDL Reports Second Quarter 2026 Financial and Operational Results

SNDL reported a 3.7% revenue drop to $235.8 million in Q2 2026 due to market headwinds. Gross profit fell 16.6% to $56.3 million, driven by lower sales and Jeeter ramp-up costs. The company posted an operating loss of $7.8 million but improved free cash flow. SNDL also advanced its acquisition of Parallel's medical cannabis assets.

Read more →
-SNDL
Jul 27, 2026
SNDLGeneral
▲ +6.7%on this newsshared move

SNDL Announces Completion of Parallel Asset Acquisition and Positions for Nasdaq-Consolidated U.S. Medical Cannabis Operations

SNDL Inc. completed the acquisition of assets from Surterra Holdings, enhancing its position in the U.S. medical cannabis market. This transaction reduces Parallel's debt and provides SNDL with significant economic exposure. The company aims to convert this indirect stake into direct holdings, positioning itself for growth in states like Florida, Texas, and Massachusetts.

Read more →
-SNDL
Jul 15, 2026
SNDLConferences/Events

SNDL to Report Second Quarter 2026 Financial Results on July 28, 2026

SNDL Inc. will release its second quarter 2026 financial results on July 28, 2026. The results will be available before market opening. Following this, a conference call and webcast will occur at 10:00 a.m. EDT. SNDL is a leading cannabis and liquor retailer in Canada.

Read more →
-SNDL
May 27, 2026
SNDLGeneral

SNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores

SNDL announced that its acquisition of Ontario cannabis stores from 1CM will not proceed due to prolonged regulatory reviews. The second closing, which involved acquiring 27 stores for $27.2 million, is not expected to happen before the May 31, 2026 deadline. However, SNDL has completed the first closing and will redirect funds towards share repurchases.

Read more →
-SNDL
Apr 29, 2026
SNDLGeneral
▼ -10.5%on this news

SNDL Reports First Quarter 2026 Financial and Operational Results

SNDL Inc. reported a net revenue of $195.9 million for Q1 2026, a 4.4% decrease from the previous year. The company faced challenges due to market softness in both liquor and cannabis segments, resulting in an operating loss of $9.1 million. Despite these setbacks, SNDL is implementing initiatives to enhance profitability and has a strong cash position.

Read more →
-SNDL
Apr 29, 2026
SNDLGeneral
▼ -10.5%on this news

SNDL Inc. Condensed Consolidated Interim Financial Statements For the three months ended

SNDL Inc. has released its condensed consolidated interim financial statements for the three months ended March 31, 2026. The company reported a decrease in net revenue and an increased operating loss compared to the same period last year. Additionally, the accumulation of shareholder equity showed only a slight improvement in the company's financial position. The overall performance reflects ongoing challenges in managing costs and generating revenue.

Read more →
-SNDL
Apr 15, 2026
SNDLConferences/Events

SNDL to Report First Quarter 2026 Financial Results on April 29, 2026

SNDL Inc. will release its first quarter 2026 financial results on April 29, 2026, before the market opens. A conference call and webcast will follow at 10:00 a.m. EDT the same day. The company is a leading cannabis retailer in Canada with a wide range of brands.

Read more →
-SNDL
Nov 4, 2025
SNDLGeneral
▼ -15.1%on this news

SNDL Inc. Condensed Consolidated Interim Financial Statements For the three and nine months ended

SNDL Inc. has released its condensed consolidated interim financial statements for the three and nine months ending September 30, 2025. The company reported a net revenue increase to CAD 693,902 for the nine-month period, with a gross profit of CAD 188,419. However, SNDL also noted a net loss attributable to its owners of CAD 25,141, reflecting ongoing challenges despite some increases in cash reserves and operating cash flow. Total assets decreased from CAD 1,349,242 to CAD 1,318,061, indicating potential financial strain.

Read more →
-SNDL
Jul 31, 2025
SNDLGeneral
▲ +19.4%on this news

SNDL Announces 2025 Annual and Special Meeting

SNDL Inc. held its Annual and Special Meeting of Shareholders where several key resolutions were approved. Shareholders fixed the number of directors at seven and elected all nominees with overwhelming support. The company also reappointed CBIZ Inc. as its auditors and approved its Stock Option Plan along with Restricted and Performance Share Unit Plan. These decisions reflect strong confidence among shareholders in the company's governance and future direction.

Read more →
-SNDL
Jul 31, 2025
SNDLGeneral
▲ +19.4%on this news

SNDL Reports Second Quarter 2025 Financial and Operational Results

SNDL Inc. reported its financial results for the second quarter of 2025, marking a pivotal milestone with positive operating income and net earnings for the first time. The company noted substantial growth across its business segments, particularly in cannabis, which outpaced the overall market growth. SNDL's liquor retail segment also showed resilience with sales growth despite fewer store locations. The company's strong financial position, highlighted by no debt and substantial cash reserves, positions it favorably for future opportunities.

Read more →
-SNDL
Jul 31, 2025
SNDLGeneral
▲ +19.4%on this news

SNDL Inc. Condensed Consolidated Interim Financial Statements For the three and six months ended

SNDL Inc. has released its condensed consolidated interim financial statements for the second quarter and first half of 2025. The company reported a net revenue increase to CAD 244,769 but also faced a net loss of CAD 11,822 for the first half of the year. Additionally, the company's accumulated deficit rose to CAD 1,299,404. Despite improvements in gross profit to CAD 67,601, the overall financial picture indicates significant challenges alongside some positive revenue growth.

Read more →
-SNDL
Jul 11, 2025
SNDLConferences/Events

SNDL to Announce Second Quarter 2025 Financial Results on July 31, 2025

SNDL Inc. has announced that it will release its second quarter 2025 financial results on July 31, 2025. The results are set to be disclosed before the market opens. Following the release, SNDL will host a conference call and webcast to discuss the results. The company operates as one of the largest vertically integrated cannabis companies in Canada and is a significant retailer in the liquor and cannabis sectors.

Read more →
-SNDL
Jun 20, 2025
SNDLConferences/Events

SNDL INC. NOTICE OF MEETING AND INFORMATION CIRCULAR DATED JUNE 20, 2025 FOR THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD VIRTUALLY ON JULY 29, 2025 AT 10:00 a.m. (Toronto Time) SNDL INC. NOTICE OF ANNUAL AN

SNDL Inc. has announced that its annual and special meeting of shareholders will be held virtually on July 29, 2025, at 10:00 a.m. Toronto Time. The meeting will focus on several important matters including the election of directors and the approval of compensation plans. Shareholders are encouraged to participate and have been provided detailed information on how to attend and vote. The notice includes key details about the process of proxy voting and participation for registered and beneficial shareholders.

Read more →
-SNDL
May 1, 2025
SNDLGeneral
▼ -5.4%on this news

SNDL Reports First Quarter 2025 Financial and Operational Results

SNDL Inc. reported its financial and operational results for the first quarter of 2025, revealing a record gross margin and improvements in free cash flow. The company is in the process of acquiring 32 cannabis retail stores and launched a Rise Rewards loyalty program aimed at engaging customers more effectively. Despite these positive developments, SNDL faces operational losses and declines in the liquor retail segment, which may impact future performance. The Board has also initiated a strategic review regarding U.S. cannabis market operations and exchange listing options to enhance business growth.

Read more →

About SNDL Inc.

2,604 employees sndl.com
BIOPHARMAWATCH ELITE
Trade the next SNDL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime